Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ wholly owned subsidiary has launched the Authorized Generic (AG) versions for all strengths of Benicar, Benicar HCT, Azor and Tribenzor in US.

The pharma major has launched Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar  (olmesartan medoxomil) tablets; Olmesartan Medoxomil-Hydrochlorothiazide tablets - therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar HCT  (olmesartan medoxomil-hydrochlorothiazide) tablets; Amlodipine Besylate-Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.’s Azor (amlodipine and olmesartan medoxomil) tablets; and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.’s Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets.

The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period. Benicar, Benicar HCT, Azor and Tribenzor recorded US sales of approximately $2.5 billion for the 12 months ending August 31, 2016, as per IMS Health.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.